The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Anti-miR-33 Therapy Does Not Alter the Progression of Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice
Open accessAbstract
Objective—: To determine the efficacy of long-term anti-miR-33 therapy on the progression of atherosclerosis in high-fat, high-cholesterol–fed Ldlr –/– mice. Methods and Results—: Ldlr –/– mice received saline, or control or anti-miR-33 oligonucleotides once a week for 14 weeks. The treatment was effective, as measured by reduced levels of hepatic miR-33 and increased hepatic expression of miR-33 targets. Analysis of plasma samples revealed an initial elevation in high-density lipoprotein cholesterol after 2 weeks of treatment that was not sustained by the end of the experiment. Additionally, we found a significant increase in circulating triglycerides in anti-miR-33–treated mice, compared with controls. Finally, examination of atheromata revealed no significant changes in the size or composition of lesions between the 3 groups. Conclusion—: Prolonged silencing of miR-33 fails to maintain elevated plasma high-density lipoprotein cholesterol and does not prevent the progression of atherosclerosis in Ldlr –/– mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, other similar studies did not observe any beneficial effects of anti-miR-33 therapy on atherogenesis (Marquart et al., 2013).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Marquart et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Another study did not find reduced aortic lesions in anti-miR-33 treated mice (Marquart et al., 2013).”
From Genetic dissection of the impact of miR-33a and miR-33b during the progression of atherosclerosis (2017) · cites this paper as Marquart et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MiR-33 Contributes to the Regulation of Cholesterol Homeostasis
Rayner, K. J., Suárez, Y., Dávalos, A., Parathath, S., Fitzgerald, M. L., Tamehiro, N., Fisher, E. A., Moore, K. J., & Fernández-Hernando, C. (2010) · Science · doi:10.1126/science.1189862 · Cited by 1,260
MicroRNA-33 and the SREBP Host Genes Cooperate to Control Cholesterol Homeostasis
Najafi-Shoushtari, S. H., Kristo, F., Li, Y., Shioda, T., Cohen, D. E., Gerszten, R. E., & Näär, A. M. (2010) · Science · doi:10.1126/science.1189123 · Cited by 957
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Rayner, K. J., Esau, C. C., Hussain, F. N., McDaniel, A. L., Marshall, S. M., van Gils, J. M., Ray, T. D., Sheedy, F. J., Goedeke, L., Liu, X., et al. (2011) · Nature · doi:10.1038/nature10486 · Cited by 706
Rayner, K. J., Sheedy, F. J., Esau, C. C., Hussain, F. N., Temel, R. E., Parathath, S., van Gils, J. M., Rayner, A. J., Chang, A. N., Suarez, Y., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57275 · Cited by 690 · cited 3×
“increase HDL-c and accelerate the regression of atherosclerotic lesions in hyperlipidemic Ldlr mice switched to standard chow diet.(7) However, no reports are yet available”
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling
Dávalos, A., Goedeke, L., Smibert, P., Ramírez, C. M., Warrier, N. P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102281108 · Cited by 670
miR-33 links SREBP-2 induction to repression of sterol transporters
Marquart, T. J., Allen, R. M., Ory, D. S., & Baldán, Á. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005191107 · Cited by 562
Self-citationHorie, T., Ono, K., Horiguchi, M., Nishi, H., Nakamura, T., Nagao, K., Kinoshita, M., Kuwabara, Y., Marusawa, H., Iwanaga, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008499107 · Cited by 384
Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*
Gerin, I., Clerbaux, L.-A., Haumont, O., Lanthier, N., Das, A. K., Burant, C. F., Leclercq, I. A., MacDougald, O. A., & Bommer, G. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152090 · Cited by 382
Is it time to revise the HDL cholesterol hypothesis?
Rader, D. J., & Tall, A. R. (2012) · Nature Medicine · doi:10.1038/nm.2937 · Cited by 279
MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice
Horie, T., Baba, O., Kuwabara, Y., Chujo, Y., Watanabe, S., Kinoshita, M., Horiguchi, M., Nakamura, T., Chonabayashi, K., Hishizawa, M., et al. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.003376 · Cited by 220
Cited by
Sorted by citations
Items 101–110 of 110
RNAi-based anti-cancer strategies - targeting the proto-oncogene PIM1 and oncogenic miRNAs
Thomas, M. (2013) · open_UMR Marburg DSpace 10.0 (Philipps-Universität Marburg) · doi:10.17192/z2013.0238
Physiological and Pathological Functions of Mammalian MicroRNAs
Ma, X., Wang, L., Cao, Z., Hu, H., Lu, Z., Xu-Monette, Z. Y., Young, K. H., & Li, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95612-5
Epigenetic factors in atherogenesis: MicroRNA
Smirnova, A. V., Sukhorukov, V. N., Карагодин, В. П., & Orekhov, A. N. (2016) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s199075081603015x
Therapeutic Targeting of High-Density Lipoprotein Metabolism
deGoma, E. M., & Rader, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00044-x
Saenz‐Pipaon, G., Wacker, B. K., Bi, L., Stamatikos, A., & Dichek, D. A. (2024) · Biology · doi:10.3390/biology13120965 · Cited by 1
Role of ncRNAs in plaque development, progression, and stability
Nossent, A. Y., Mitić, T., Sachs, N., Greco, S., & Martelli, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33064-3.00015-3
Delgado, S. E. (2017) · theses.fr (ABES) · doi:10.70675/d8aabbbazd750z4f3cz824czd7ae7217f99a
Faulconnier, Y., Pires, J., Ye, T., Pawłowski, K., & Leroux, C. (2026) · Comparative Biochemistry and Physiology - Part D:Genomics and Proteomics · doi:10.1016/j.cbd.2026.101995
Citrin, K. M., Huang, Y., Ramos-Perez, A., Castellanos, C., Canfrán‐Duque, A., Zhang, X., Chaube, B., de Urturi, D. S., Gómez‐Coronado, D., Libreros, S., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120800
Metadata
- Authors
- Marquart, T. J., Wu, J., Lusis, A. J., & Baldán, Á.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2013-03
- Volume
- 33
- Issue
- 3
- Pages
- 455-458
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC3587119
- OpenAlex
- W2169384530
- Cited by
- 110
- References
- 14
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 14 · 2016: 18 · 2015: 15 · 2014: 18 · 2013: 16
- FWCI
- 22.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Saint Louis University
- National Heart, Lung, and Blood Institute (HL030568, HL095154, P01HL030568, R01HL095154, HL107794, R01HL107794)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- miR-33, atherosclerosis progression, LDL receptor-deficient mice, HDL cholesterol, high-fat high-cholesterol diet, microRNA silencing
- MeSH terms
- Animals, Aorta, Aortic Diseases, Cholesterol, Dietary, Disease Models, Animal, Cholesterol, HDL, Liver, Male, Receptors, LDL, Time Factors, Triglycerides, Biomarkers, Down-Regulation, Oligonucleotides, Antisense, Mice, Knockout, Disease Progression, MicroRNAs, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
